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Mouse model studies have found that the S100A gene cluster is profoundly 
suppressed in KS mutations, explaining this complexes’ important role in 
cardiogenesis. Other pathways implicated in pathology include: wnt/ beta-
catenin, cardiac stem cell differentiation, cAMP signaling, b-cell development, 
and cardiac beta-adrenergic signaling [6].
Zebrafish studies simulating KS mutations show that both proteins play a role 
in early development, especially within craniofacial, brain, and cardiac 
morphogenesis [14]. Haploisufficiency in either of these genes results 
hypoplasia of pharyngeal arches, explaining KS craniofacial abnormalities (fig 
6). Cardiac development was impaired specifically within cardiac looping 
involution, resulting in septal defects, and abnormal development of the 
ventricles and atria. Embryological development of the midbrain also appeared 
to be altered. Examination of midbrain cells indicated neuronal precursor cells 
had an impaired ability to differentiate [14]. 
Neurological Impairment
Patients often present mild intellectual impairment, as well as experience partial 
seizures. Neurological structures do not seem grossly affected, though 
hippocampal atrophy and enlargement of the ventricles have been found [2]. It is 
hypothesized that seizures are the result of cerebral hyperexcitability rather than 
neurological malformations. Mouse models of heterozygous KMT2D mutation 
exhibited a decreased dente gyrus mass and lowered hippocampal functioning, 
supporting prior findings of neurological impairment in KS. Interestingly, 
researchers of this study found that inhibition of histone deacetylase could 
mitigate neurological impairment during development in these models [3] . 
Immunological Deficiency
KS seems to generate symptoms in patients that are similar to common variable 
immunodeficiency as a result of either autoimmunity, or decreased serum 
antibodies. Patients often suffer from chronic upper respiratory infections, and 
otitis media, which may contribute to hearing loss [13]. A case study of 14 female 
patients with KMT2D mutations showed that lymphocyte proliferation did not 
seem to be markedly affected, though differentiation of memory cells was 
impaired. Cytokine production was also reduced (IL-2, IL-12, IFN gamma), as 
well as serum Ab IgG, IgG2, and IgA. CD molecules also appeared to be reduced 
[12]. Patients treated with supplemental antibodies seemed to have reduced 
occurrence of bacterial infection [12]. 
Cardiac Abnormalities
Congenital heart defects are found in roughly 40-50% of patients with KS, and 
are not limited to either of the two mutations. Frequently found malformations 
are atrial septal defects, ventricular septal defects and aortic coarctation [4]. 
Surgical intervention is sometimes required to mitigate these defects. KMT2D 
haploinsufficient mouse models show a general narrowing of the ascending 
aorta. Those with a complete KMT2D knockout exhibit decreased cardiomyocyte 
proliferation and inviability, implicating this gene’s role in cardiac formation 
during development [1].
Diagnosis of KS can be confirmed via 
genetic testing for mutations in 
KMT2D or KMD6A gene mutations, 
though 30% of patients with KMS do 
not have a mutation in either of these 
genes. Blood tests have been made 
available to those who may suspect 
this mutation runs in their family, 
including fetal blood tests. 
Patients with an unknown mutation 
are diagnosed based on 
symptomology, patient history, and 
thorough clinical evaluation. Symptom 
based diagnosis of KS involves an 
individual exhibiting at least 4 of these 
5 common symptoms: distinctive facial 
features (fig. 4), skeletal abnormalities 
(fig. 1), intellectual disability, 
dermatoglyphic abnormalities such as 
persistent fetal finger pads, and 
postnatal short stature (fig. 2)
Symptoms such as hypotonia can often 
be the result of hyperinsulinism, 
which may be underdiagnosed in 
patients with presenting with a 
mutation in KMD6A [5].
Kabuki Syndrome (KS) is a rare genetic disorder characterized by multiple developmental abnormalities, and varying degrees of cognitive impairment. Hallmark features of this disorder typically include distinctive facial features, skeletal and 
dermatoglyphic abnormalities, intellectual disability, and postnatal short stature. These features form the basis for diagnosis, though individuals suffering from KS will present a host of other ailments spanning from cardiovascular and digestive 
abnormalities, to immunological deficiencies. The majority of cases arise due to de novo mutations, but KS can be inherited through autosomal dominance. Genes identified as suspect in the disease’s manifestation include KMT2D and KMD6A, 
which are both involved in histone modification. Mutations in these genes account for 75% of those clinically diagnosed with KS. Treatment is centered around the mitigation of symptomology unique to each patient, and early diagnosis is crucial 
to improving prognosis. Recent findings have shown that neurological and immunological pathology has potential for improvement in animal models, as well as the role of hypoinsulinism in the manifestation of hypotonia and growth retardation. 
This presentation seeks to review recent data on KS, and to provide information on the role of development in this disease. 
I. Abstract
Figure 4. Typical facial gestalt 
seen in KS. Craniofacial 
abnormalities include 
pronounced ears, depressed nasal 
tip, arched eyebrows, and 
elongated palpebral fissures [7].
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Figure 1. Elongated halluces of 
the feet in two patients with KS. 
A common example of skeletal 
abnormalities [11].
Figure 2. 
Persistent fetal 
finger pads as 
found in a patient 
with KS [15].
II. Diagnosis IV. Effects on Development in Select Organ Systems
Figure 5. Comparison of 
embryological 
pharyngeal crests in WT 
and knockout zebrafish 
[14].
V. References
III. Mutations
KMT2D and KMD6A both code for 
methyltransferases involved in histone 
modification and chromatin modeling (fig. 
3), and are part of the large protein complex 
ASCOM [9,10]. This complex seems to play 
an important role in expressing cell 
signaling intermediaries important to 
development (tab. 1). Unfortunately, the 
mechanisms behind these interactions are 
poorly understood, though the ASCOM 
complex appears to be essential in the 
differential expression of many genes.
Table 1. Signaling pathways downregulated in KMT2D mutations. 
Implicates ASCOM’s role in development [6].
Figure 3. Chromosomal locations of KMT2D (above) and KMD6A (below). 
KMT2D codes for Histone-lysine N methyltransferase 2D 
[9], and KMD6A codes for Lysine Demethylase 6A [10]..
